Appia Bio
Maha Qubain has held a variety of roles in the medical and research fields since 2013. Maha began their career as a Team Member at the Office of the President of the Undergraduate Student Association Council at UCLA, and then held the position of Assistant I at UCLA. In 2014, they were the Vice President of Operation Smile at UCLA and External Outreach Director for All Of Us: A Campaign To Rethink Mental Health. From 2015 to 2017, they were a Research Associate at the UCLA David Geffen School of Medicine Nephrology Department. From 2017 to 2021, they were a Research Associate in Cell Biology and Cell Therapy Specialist at Kite Pharma. Most recently, they have been a Senior Research Associate at MiNK Therapeutics since 2021, and will be a Senior Research Associate I at Appia Bio starting in 2022.
Maha Qubain completed their high school education at The Ahliyyah School for Girls from 2000 to 2012, where they obtained their International Baccalaureate Diploma. Maha then went on to pursue a Bachelor's Degree in Microbiology, Immunology and Molecular Genetics from the University of California, Los Angeles from 2012 to 2016.
This person is not in any teams
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).